Literature DB >> 26405587

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.

Murali Janakiram1, Jordan M Chinai2, Aimin Zhao3, Joseph A Sparano4, Xingxing Zang1.   

Abstract

We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

Entities:  

Keywords:  B7 family; CD28 family; HHLA2; TMIGD2; angiogenesis; immunosuppression; immunotherapy; ligand; receptor; tumor microenvironment

Year:  2015        PMID： 26405587      PMCID： PMC4570140          DOI： 10.1080/2162402X.2015.1026534

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3).

Authors:  D L Mager; D G Hunter; M Schertzer; J D Freeman
Journal:  Genomics       Date:  1999-08-01       Impact factor: 5.736

Review 2.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.

Authors:  Kim C Ohaegbulam; Amer Assal; Eszter Lazar-Molnar; Yu Yao; Xingxing Zang
Journal:  Trends Mol Med       Date:  2014-10-30       Impact factor: 11.951

3.  Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC.

Authors:  Martin F Flajnik; Tereza Tlapakova; Michael F Criscitiello; Vladimir Krylov; Yuko Ohta
Journal:  Immunogenetics       Date:  2012-04-11       Impact factor: 2.846

4.  Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.

Authors:  Murali Janakiram; Jordan M Chinai; Susan Fineberg; Andras Fiser; Cristina Montagna; Ramadevi Medavarapu; Ekaterina Castano; Hyungjun Jeon; Kim C Ohaegbulam; Ruihua Zhao; Aimin Zhao; Steven C Almo; Joseph A Sparano; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2014-12-30       Impact factor: 12.531

Review 5.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

6.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.

Authors:  Ruihua Zhao; Jordan M Chinai; Susan Buhl; Lisa Scandiuzzi; Anjana Ray; Hyungjun Jeon; Kim C Ohaegbulam; Kaya Ghosh; Aimin Zhao; Matthew D Scharff; Xingxing Zang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

7.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

8.  Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis.

Authors:  Nader Rahimi; Kobra Rezazadeh; John E Mahoney; Edward Hartsough; Rosana D Meyer
Journal:  Mol Biol Cell       Date:  2012-03-14       Impact factor: 4.138

9.  B7-H5 costimulates human T cells via CD28H.

Authors:  Yuwen Zhu; Sheng Yao; Bettina P Iliopoulou; Xue Han; Mathew M Augustine; Haiying Xu; Ryan T Phennicie; Sarah J Flies; Megan Broadwater; William Ruff; Janis M Taube; Linghua Zheng; Liqun Luo; Gefeng Zhu; Jianzhu Chen; Lieping Chen
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919
  9 in total
  54 in total

1.  HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.

Authors:  Li Wei; Liang Tang; Haiyan Chang; Song Huo; Yan Li
Journal:  Hum Cell       Date:  2019-09-24       Impact factor: 4.174

2.  Considering B7-CD28 as a family through sequence and structure.

Authors:  Sean M West; Xiaodi A Deng
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-17

3.  CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.

Authors:  Yu Tian; Yi Sun; Fan Gao; Michelle R Koenig; Alexander Sunderland; Yuki Fujiwara; Robert J Torphy; Lieping Chen; Barish H Edil; Richard D Schulick; Yuwen Zhu
Journal:  Oncoimmunology       Date:  2018-11-05       Impact factor: 8.110

4.  HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.

Authors:  Haiying Cheng; Murali Janakiram; Alain Borczuk; Juan Lin; Wanglong Qiu; Huijie Liu; Jordan M Chinai; Balazs Halmos; Roman Perez-Soler; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-08-23       Impact factor: 12.531

5.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

6.  Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Authors:  Haiying Cheng; Alain Borczuk; Murali Janakiram; Xiaoxin Ren; Juan Lin; Amer Assal; Balazs Halmos; Roman Perez-Soler; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2018-01-26       Impact factor: 12.531

Review 7.  New B7 Family Checkpoints in Human Cancers.

Authors:  Ling Ni; Chen Dong
Journal:  Mol Cancer Ther       Date:  2017-07       Impact factor: 6.261

8.  Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.

Authors:  Chaoqi Zhang; Zhen Zhang; Feng Li; Zhibo Shen; Yamin Qiao; Lifeng Li; Shasha Liu; Mengjia Song; Xuan Zhao; Feifei Ren; Qianyi He; Bo Yang; Ruitai Fan; Yi Zhang
Journal:  Oncoimmunology       Date:  2018-08-23       Impact factor: 8.110

9.  H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.

Authors:  Min Luo; Yao Xiong; Yan Lin; Rong Liang; Yongqiang Li; Lianying Ge
Journal:  Med Sci Monit       Date:  2021-05-15

10.  HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer.

Authors:  Guocai Xu; Yuanyuan Shi; Xiaoting Ling; Dongyan Wang; Yunyun Liu; Huaiwu Lu; Yongpai Peng; Bingzhong Zhang
Journal:  Cancer Cell Int       Date:  2021-05-07       Impact factor: 5.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.